EA201101231A1 - Способы предотвращения или снижения риска смертности - Google Patents
Способы предотвращения или снижения риска смертностиInfo
- Publication number
- EA201101231A1 EA201101231A1 EA201101231A EA201101231A EA201101231A1 EA 201101231 A1 EA201101231 A1 EA 201101231A1 EA 201101231 A EA201101231 A EA 201101231A EA 201101231 A EA201101231 A EA 201101231A EA 201101231 A1 EA201101231 A1 EA 201101231A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- risk
- methods
- mortality
- prevent
- reduce
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Изобретение относится к способам предотвращения или снижения риска смертности в результате любой из причин, включающих, но не ограничивающихся сердечно-сосудистыми заболеваниями у млекопитающих, в частности у людей, включающим введение указанному млекопитающему или человеку ингибитора дипептидилпептидазы 4 (DPP-IV). Кроме того, изобретение относится к способам предотвращения или снижения риска несмертельного инфаркта миокарда и/или несмертельного инсульта у млекопитающих, в частности у людей, включающим введение указанному млекопитающему или человеку е ингибитора DPP-IV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16415309P | 2009-03-27 | 2009-03-27 | |
US16539909P | 2009-03-31 | 2009-03-31 | |
PCT/US2010/028933 WO2010111665A1 (en) | 2009-03-27 | 2010-03-26 | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201101231A1 true EA201101231A1 (ru) | 2012-06-29 |
Family
ID=42199886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201101231A EA201101231A1 (ru) | 2009-03-27 | 2010-03-26 | Способы предотвращения или снижения риска смертности |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100256153A1 (ru) |
EP (1) | EP2411005A1 (ru) |
JP (1) | JP2012522015A (ru) |
KR (1) | KR20110135411A (ru) |
CN (1) | CN102448456A (ru) |
AU (1) | AU2010229653A1 (ru) |
BR (1) | BRPI1013500A2 (ru) |
CA (1) | CA2756786A1 (ru) |
CL (1) | CL2011002381A1 (ru) |
EA (1) | EA201101231A1 (ru) |
IL (1) | IL214991A0 (ru) |
MX (1) | MX2011009852A (ru) |
SG (2) | SG174504A1 (ru) |
WO (1) | WO2010111665A1 (ru) |
ZA (1) | ZA201106756B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014230096C1 (en) * | 2013-03-15 | 2019-08-29 | Boehringer Ingelheim International Gmbh | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
KR101598612B1 (ko) * | 2013-08-29 | 2016-02-26 | 재단법인 아산사회복지재단 | Dpp-4 억제제를 포함하는 혈관 또는 심장판막 석회화의 예방 또는 치료용 조성물 |
WO2016034710A1 (en) * | 2014-09-05 | 2016-03-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of sitagliptin |
SG11201707008SA (en) * | 2015-02-27 | 2017-09-28 | Asan Found | Composition for preventing or treating valve calcification, containing dpp-4 inhibitor |
CN107635512A (zh) * | 2015-04-15 | 2018-01-26 | 康斯瓦维有限责任公司 | 用于抑制天然心脏瓣膜、被支撑的心脏瓣膜或生物假体的狭窄、阻塞或钙化的装置和方法 |
US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
WO2018049008A1 (en) * | 2016-09-07 | 2018-03-15 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
GB201619861D0 (en) * | 2016-11-24 | 2017-01-11 | Narodden Salomon | Treatments for heart failure and cardiac ischaemic reperfusion injury |
US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
CA3164933A1 (en) * | 2020-01-08 | 2021-07-15 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (ru) | 1974-06-07 | 1981-03-18 | ||
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
DE3581638D1 (de) | 1984-12-04 | 1991-03-07 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
KR900001212B1 (ko) | 1985-10-25 | 1990-02-28 | 산도즈 파마슈티칼스 코오포레이숀 | 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도 |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
GB2205837B (en) | 1987-05-22 | 1991-11-20 | Squibb & Sons Inc | Phosphorus-containing hmg-coa reductase inhibitors |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5447954A (en) | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
US5662934A (en) | 1993-01-05 | 1997-09-02 | Najarian; Thomas | Compositions and methods for lowering cholesterol while maintaining antioxidant levels |
SG45369A1 (en) | 1993-01-19 | 1998-10-16 | Warner Lambert Co | Stable oral ci-981 formulation and process of preparing same |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5698527A (en) | 1995-08-08 | 1997-12-16 | Merck & Co., Inc. | Steroidal glycosides as antihyperlipidemic agents |
WO1997021993A2 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
IL117702A0 (en) | 1996-03-28 | 1996-07-23 | Tel Aviv Medical Center Resear | Drug for hyperlipoproteinemia |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE19622222A1 (de) | 1996-06-03 | 1997-12-04 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide |
WO1997048701A1 (en) | 1996-06-20 | 1997-12-24 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
TW475931B (en) | 1997-10-08 | 2002-02-11 | Sankyo Co | A substituted condensed heterocyclic compound |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
WO2000015201A2 (en) | 1998-09-10 | 2000-03-23 | Forbes Medi-Tech Inc. | Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
AU767245B2 (en) | 1998-11-25 | 2003-11-06 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
JP2002537407A (ja) | 1999-02-24 | 2002-11-05 | ジョンズ・ホプキンス・ユニバーシティ | 血清コレステロールを調節するための組成物及び方法。 |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
BR0315688A (pt) | 2002-11-22 | 2005-09-06 | Japan Tobacco Inc | Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas |
US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
KR20150132601A (ko) * | 2003-11-17 | 2015-11-25 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
TW200536827A (en) * | 2004-05-04 | 2005-11-16 | Bristol Myers Squibb Co | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
US7214702B2 (en) * | 2004-05-25 | 2007-05-08 | Bristol-Myers Squibb Company | Process for producing a dipeptidyl peptidase IV inhibitor |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US20080269311A1 (en) * | 2004-07-14 | 2008-10-30 | Edwin Bernard Villhauer | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors |
WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
US20080070922A1 (en) * | 2004-10-08 | 2008-03-20 | Bryan Burkey | Combination of Organic Compounds |
EA200700851A1 (ru) | 2004-10-15 | 2007-12-28 | Байер Фармасьютикалс Корпорейшн | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения |
EP1848687A1 (en) | 2005-02-07 | 2007-10-31 | F. Hoffmann-Roche AG | Inhibitors of diacylglycerol acyltransferase (dgat) |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
CN101208085B (zh) * | 2005-06-10 | 2011-01-05 | 诺瓦提斯公司 | 1-[(3-羟基-金刚烷基-1-基氨基)-乙酰基]-吡咯烷基-2(s)-腈的调释制剂 |
CA2610188A1 (en) | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
WO2007006790A2 (en) * | 2005-07-12 | 2007-01-18 | Novartis Ag | Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
-
2010
- 2010-03-26 JP JP2012502311A patent/JP2012522015A/ja active Pending
- 2010-03-26 WO PCT/US2010/028933 patent/WO2010111665A1/en active Application Filing
- 2010-03-26 AU AU2010229653A patent/AU2010229653A1/en not_active Abandoned
- 2010-03-26 KR KR1020117025313A patent/KR20110135411A/ko unknown
- 2010-03-26 SG SG2011068301A patent/SG174504A1/en unknown
- 2010-03-26 EA EA201101231A patent/EA201101231A1/ru unknown
- 2010-03-26 BR BRPI1013500A patent/BRPI1013500A2/pt active Search and Examination
- 2010-03-26 MX MX2011009852A patent/MX2011009852A/es unknown
- 2010-03-26 US US12/748,140 patent/US20100256153A1/en not_active Abandoned
- 2010-03-26 CA CA2756786A patent/CA2756786A1/en not_active Abandoned
- 2010-03-26 SG SG10201501882TA patent/SG10201501882TA/en unknown
- 2010-03-26 CN CN2010800234127A patent/CN102448456A/zh active Pending
- 2010-03-26 EP EP10712234A patent/EP2411005A1/en not_active Withdrawn
-
2011
- 2011-09-05 IL IL214991A patent/IL214991A0/en unknown
- 2011-09-15 ZA ZA2011/06756A patent/ZA201106756B/en unknown
- 2011-09-27 CL CL2011002381A patent/CL2011002381A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG174504A1 (en) | 2011-10-28 |
EP2411005A1 (en) | 2012-02-01 |
US20100256153A1 (en) | 2010-10-07 |
KR20110135411A (ko) | 2011-12-16 |
BRPI1013500A2 (pt) | 2016-04-05 |
JP2012522015A (ja) | 2012-09-20 |
MX2011009852A (es) | 2011-09-29 |
WO2010111665A1 (en) | 2010-09-30 |
AU2010229653A1 (en) | 2011-10-20 |
SG10201501882TA (en) | 2015-06-29 |
CN102448456A (zh) | 2012-05-09 |
CL2011002381A1 (es) | 2012-03-23 |
CA2756786A1 (en) | 2010-09-30 |
IL214991A0 (en) | 2011-11-30 |
ZA201106756B (en) | 2013-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201101231A1 (ru) | Способы предотвращения или снижения риска смертности | |
PA8852901A1 (es) | Inhibidores de proteina cinasa | |
UY32380A (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
UY32820A (es) | Composiciones dermatologicas de antagonistas del receptor dp2 | |
EA201390060A1 (ru) | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний | |
GT200600280A (es) | Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo | |
IN2012DN00721A (ru) | ||
MA32372B1 (fr) | INHIBITEURS DPP-IV à UTILISER DANS LE TRAITEMENT DE LA NAFLD | |
TN2011000201A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase - iv inhibitors for the treatment or prevention of diabetes | |
MX370429B (es) | Composiciones farmacéuticas que comprenden bi-1356 y metformina. | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
CR20110339A (es) | Compuestos útiles para inhibir chk1 | |
WO2011106106A3 (en) | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae | |
NO20074824L (no) | Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter | |
BR112012011478A2 (pt) | composições fosfolipídicas terapêuticas concentradas. | |
EA201291310A1 (ru) | Композиция ингибитора jak для местного применения | |
EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
SG178984A1 (en) | Novel pyrimidine and triazine hepcidine antagonists | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
EA201100756A1 (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином | |
EA201100755A1 (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином | |
CY1109685T1 (el) | Χρησιμοποιηση συμπλοκων ενωσεων σιδηρου(ιιι) | |
IN2012DN03271A (ru) | ||
DOP2011000335A (es) | Combinacion antitumoral que comprende ave8062 y sorafenib | |
PE20170469A1 (es) | Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo |